指南与共识头颈与中枢神经肿瘤支持与姑息治疗

非手术抗肿瘤治疗所致唾液腺功能减退和/或口干:ISOO/MASCC/ASCO指南

Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2021-07-20

该指南由MASCC/ISOO与ASCO组织多学科专家组制定,基于2009年1月至2020年6月发表的随机对照试验及此前系统评价,提供预防和管理非手术抗肿瘤治疗所致唾液腺功能减退和/或口干的循证推荐。共纳入58篇文献,多数证据集中于头颈癌放疗情境。推荐尽可能使用保留组织的放疗模式,其他预防措施证据较弱;管理方面中等质量证据支持局部黏膜润滑剂、唾液替代品和刺激唾液反射的药物。

要点

  • 头颈癌放疗应尽可能采用保留组织的放疗模式以降低唾液腺功能减退和口干风险。
  • 放疗期间可考虑bethanechol和针灸等风险降低干预。
  • 出现唾液腺功能减退和/或口干时,可用局部黏膜润滑剂、唾液替代品及无糖含片或口香糖。

核心结论

  • 头颈癌放疗应尽可能使用保留组织的放疗模式以降低唾液腺功能减退和口干风险。
  • 其他预防干预证据较弱或不足;管理方面中等质量证据支持局部黏膜润滑剂、唾液替代品和刺激唾液反射的药物。

研究设计与样本

  • MASCC/ISOO与ASCO召集多学科专家组制定循证推荐。
  • 检索PubMed、EMBASE和Cochrane Library2009年1月至2020年6月发表的随机对照试验,并纳入MASCC/ISOO既往两项系统评价(1990—2008年),共识别58篇文献。

主要发现

  • 58篇文献中46篇涉及预防干预,12篇涉及治疗干预;多数证据集中于头颈癌放疗情境。
  • 预防头颈癌患者唾液腺功能减退和/或口干方面,保留组织的放疗模式有高质量证据。
  • 管理唾液腺功能减退和/或口干方面,局部黏膜润滑剂、唾液替代品和刺激唾液反射的药物有中等质量证据支持。

关键数值与推荐

  • 头颈癌放疗患者应尽可能使用保留组织的放疗模式。
  • 头颈癌放疗期间可提供bethanechol和针灸等风险降低干预。
  • 出现唾液腺功能减退和/或口干的患者,干预包括局部黏膜润滑剂、唾液替代品及无糖含片或口香糖。
  • 头颈癌患者放疗后可提供口服毛果芸香碱、口服西维美林、针灸或经皮电刺激。

临床怎么用

  • 头颈癌放疗计划应优先考虑保留组织的放疗技术。
  • 放疗期间可评估并提供bethanechol或针灸作为风险降低选项。
  • 对已发生口干或唾液腺功能减退者,首选局部黏膜润滑剂、唾液替代品及无糖含片或口香糖。
  • 放疗后可根据情况选用口服毛果芸香碱、西维美林、针灸或经皮电刺激。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies. METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials published between January 2009 and June 2020. The guideline also incorporated two previous systematic reviews conducted by MASCC/ISOO, which included studies published from 1990 through 2008. RESULTS: A total of 58 publications were identified: 46 addressed preventive interventions and 12 addressed therapeutic interventions. A majority of the evidence focused on the setting of radiation therapy for head and neck cancer. For the prevention of salivary gland hypofunction and/or xerostomia in patients with head and neck cancer, there is high-quality evidence for tissue-sparing radiation modalities. Evidence is weaker or insufficient for other interventions. For the management of salivary gland hypofunction and/or xerostomia, intermediate-quality evidence supports the use of topical mucosal lubricants, saliva substitutes, and agents that stimulate the salivary reflex. RECOMMENDATIONS: For patients who receive radiation therapy for head and neck cancer, tissue-sparing radiation modalities should be used when possible to reduce the risk of salivary gland hypofunction and xerostomia. Other risk-reducing interventions that may be offered during radiation therapy for head and neck cancer include bethanechol and acupuncture. For patients who develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubricants, saliva substitutes, and sugar-free lozenges or chewing gum. For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy.Additional information can be found at www.asco.org/supportive-care-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mercadante V, Jensen SB, Smith DK, et al. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. J Clin Oncol. 2021. PMID: 34283635. doi:10.1200/JCO.21.01208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。